Ubiquitin chain editing by the mammalian proteasome
Ubiquitin chain editing by the mammalian proteasome
批准号:
8688267
负责人:
Daniel J Finley
金额:
$44.12万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2011
资助国家:
美国
项目状态:
已结题
起止时间:
2011-06-01 至 2016-05-31
关键词:
Active SitesAddressAffectBindingBiochemicalBiochemistryCellsClientCodeComplementDependenceDevelopmentDiseaseDissociationEnzymesExcisionFundingGenesGeneticHandIn VitroIndividualLaboratoriesLigaseLinkMammalsMass Spectrum AnalysisMethodsModelingMusMutant Strains MiceOrthologous GeneOutputPathway interactionsPlayPredispositionProbabilityProcessPropertyProteasome BindingProteinsRegulationResistanceRoleSignal TransductionSpecificityStressSubstrate SpecificitySystemTestingTherapeuticTimeToxic effectUbiquitinWorkYeastsbasedesignin vitro Modelin vivoinhibitor/antagonistinsightinterestknockout genemulticatalytic endopeptidase complexnovelnovel therapeuticsprotein degradationreceptorresearch studyresponsesmall moleculeubiquitin ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): Since its discovery, the proteasome has generally been viewed as a passive player in the selection of substrates for degradation. This notion has recently been challenged by studies, many from this laboratory, showing that proteasomes rapidly edit ubiquitin chains and that these processes strongly regulate proteasome output. We first examined these issues in yeast, but now propose to focus on mammals, where little is being done. The regulatory systems differ between yeast and mammals, making it especially important that these questions are studied carefully in mammals. For example, whereas yeast has a single enzyme that trims chains on the proteasome, Ubp6, mammals have two: Usp14 (the Ubp6 ortholog) and Uch37. Also, our studies indicate that the influence of chain trimming on degradation rates is more dramatic in mammals. We have developed a specific, small-molecule inhibitor of Usp14. Using this inhibitor, both in vivo and in cells, we discovered an unexpectedly powerful role of chain trimming in regulating degradation. This compound is unique in providing, for the first time, a way to enhance output of the ubiquitin-proteasome pathway. Remarkably, it induces faster degradation of multiple proteotoxic proteins as well as oxidized proteins, and provides resistance to proteotoxic stress. Possible eventual therapeutic applications include, in principle, tens of known diseases in which toxic proteins are expressed or protein degradation is deficient. A screen has also been completed for Uch37, covering 130,000 compounds, and a highly selective inhibitor is in hand. Though Usp14 and Uch37 both trim chains, they seem to regulate the proteasome in distinct ways, for unknown reasons. To understand this, we will first carry out in vitro and model substrate studies testing whether the topological linkage specificity of substrate-bound ubiquitin chains provides an underlying code that could explain the substrate specificities of Usp14 and Uch37 and their effects on degradation rates. Similar model substrate work will assess whether a protein's susceptibility to unfolding by the proteasome in linked to chain trimming. What features of the substrate determine susceptibility to editing factors will be analyzed further using endogenous substrates? We will use state of the art mass spectrometry approaches to determine, on a broad, if not global, scale, which substrates in the cell are regulated via proteasomal chain editing, using the inhibitors as well and gene knockouts in mice. Relevant properties of endogenous substrates, such as the type of ubiquitin chain they carry and their ubiquitin receptor dependence, will be characterized. A final component of the editing system is Hul5, a conserved, proteasome-associated ubiquitin ligase. We have shown Hul5 extends proteasome-bound ubiquitin chains and is thus important for chain editing in yeast, where it antagonizes Ubp6. Thus far Hul5 has essentially not been studied in mammals. The results will provide important new insights into proteasome function and might have relevance to the development of novel therapeutics.
期刊论文(2)
专著(0)
科研奖励(0)
会议论文
DOI:
10.7554/elife.10510
发表时间:
2015-11-02
期刊:
eLife
影响因子:
7.7
作者:
[Xu D, Shan B, Lee BH, Zhu K, Zhang T, Sun H, Liu M, Shi L, Liang W, Qian L, Xiao J, Wang L, Pan L, Finley D, Yuan J]
通讯作者:
Yuan J
DOI:
10.1038/oncsis.2013.28
发表时间:
2013-08-19
期刊:
ONCOGENESIS
影响因子:
6.2
作者:
[Jung, H., Kim, B-G, Han, W. H., Lee, J. H., Cho, J-Y, Park, W. S., Maurice, M. M., Han, J-K, Lee, M. J., Finley, D., Jho, E-h]
通讯作者:
Jho, E-h
Regulation of Proteasome Activity
-
批准号:10406057
-
项目类别:
-
资助金额:$49.72万
-
财政年份:2022
-
负责人:Daniel J Finley
-
依托单位:
Regulation of Proteasome Activity
-
批准号:10707061
-
项目类别:
-
资助金额:$49.72万
-
财政年份:2022
-
负责人:Daniel J Finley
-
依托单位:
The proteasome in aging and neurodegenerative disease
-
批准号:10183115
-
项目类别:
-
资助金额:$43.15万
-
财政年份:2018
-
负责人:Daniel J Finley
-
依托单位:
Proteostasis Core: Quantitative global proteomics
-
批准号:10183112
-
项目类别:
-
资助金额:$25.19万
-
财政年份:2018
-
负责人:Daniel J Finley
-
依托单位:
The proteasome in aging and neurodegenerative disease
-
批准号:10432033
-
项目类别:
-
资助金额:$42.64万
-
财政年份:2018
-
负责人:Daniel J Finley
-
依托单位:
Proteostasis Core: Quantitative global proteomics
-
批准号:10432029
-
项目类别:
-
资助金额:$25.01万
-
财政年份:2018
-
负责人:Daniel J Finley
-
依托单位:
Ubiquitin chain editing by the mammalian proteasome
-
批准号:8269828
-
项目类别:
-
资助金额:$43.99万
-
财政年份:2011
-
负责人:Daniel J Finley
-
依托单位:
Ubiquitin chain editing by the mammalian proteasome
-
批准号:8473882
-
项目类别:
-
资助金额:$42.57万
-
财政年份:2011
-
负责人:Daniel J Finley
-
依托单位:
Ubiquitin chain editing by the mammalian proteasome
-
批准号:8108436
-
项目类别:
-
资助金额:$49.06万
-
财政年份:2011
-
负责人:Daniel J Finley
-
依托单位:
Functional Analysis of the Proteasome Base
-
批准号:8080023
-
项目类别:
-
资助金额:$27.03万
-
财政年份:2010
-
负责人:Daniel J Finley
-
依托单位:
Studies of Usp14 and the Ubiquitin Stress Response
-
批准号:7692187
-
项目类别:
-
资助金额:$21.19万
-
财政年份:2008
-
负责人:Daniel J Finley
-
依托单位:
Studies of Usp14 and the Ubiquitin Stress Response
-
批准号:7571004
-
项目类别:
-
资助金额:$25.35万
-
财政年份:2008
-
负责人:Daniel J Finley
-
依托单位:
Ubiquitination and Cellular Regulation
-
批准号:6763728
-
项目类别:
-
资助金额:$1.2万
-
财政年份:2004
-
负责人:Daniel J Finley
-
依托单位:
Regulation of Proteasome Activity by Ubp6 and Hul5
-
批准号:7641122
-
项目类别:
-
资助金额:$39.97万
-
财政年份:2003
-
负责人:Daniel J Finley
-
依托单位:
Regulation of Proteasome Activity by Ubp6 and Hul5
-
批准号:7494185
-
项目类别:
-
资助金额:$13.38万
-
财政年份:2003
-
负责人:Daniel J Finley
-
依托单位:
Regulation of Proteasome Activity by Ubp6 and Hul5
-
批准号:7886015
-
项目类别:
-
资助金额:$21.36万
-
财政年份:2003
-
负责人:Daniel J Finley
-
依托单位:
NEW, SALT-SENSITIVE COMPONENTS OF THE PROTEASOME
-
批准号:6570790
-
项目类别:
-
资助金额:$36.96万
-
财政年份:2003
-
负责人:Daniel J Finley
-
依托单位:
NEW, SALT-SENSITIVE COMPONENTS OF THE PROTEASOME
-
批准号:7028359
-
项目类别:
-
资助金额:$36.41万
-
财政年份:2003
-
负责人:Daniel J Finley
-
依托单位:
NEW, SALT-SENSITIVE COMPONENTS OF THE PROTEASOME
-
批准号:6861842
-
项目类别:
-
资助金额:$37.29万
-
财政年份:2003
-
负责人:Daniel J Finley
-
依托单位:
Regulation of Proteasome Activity by Ubp6 and Hul5
-
批准号:7321892
-
项目类别:
-
资助金额:$37.18万
-
财政年份:2003
-
负责人:Daniel J Finley
-
依托单位:
海外基金